Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-13
2007-11-13
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S417000
Reexamination Certificate
active
10511731
ABSTRACT:
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
REFERENCES:
patent: 4386098 (1983-05-01), Woltersdorf, Jr.
patent: 4416890 (1983-11-01), Woltersdorf, Jr.
patent: 4426388 (1984-01-01), Woltersdorf, Jr.
patent: 4599353 (1986-07-01), Bito et al.
patent: 4668697 (1987-05-01), Shepard et al.
patent: 4797413 (1989-01-01), Baldwin et al.
patent: 4824857 (1989-04-01), Goh et al.
patent: 4863922 (1989-09-01), Baldwin et al.
patent: 4883819 (1989-11-01), Bito et al.
patent: 5001153 (1991-03-01), Ueno et al.
patent: 5153192 (1992-10-01), Dean et al.
patent: 5240923 (1993-08-01), Dean et al.
patent: 5378703 (1995-01-01), Dean et al.
patent: 5541208 (1996-07-01), Garcia et al.
patent: 5573758 (1996-11-01), Adorante et al.
patent: 5925342 (1999-07-01), Adorante et al.
patent: 6924306 (2005-08-01), Garcia et al.
patent: 2005/0239787 (2005-10-01), Goetz et al.
patent: WO 89/10757 (1989-11-01), None
patent: WO 93/22318 (1993-02-01), None
patent: WO 94/28900 (1994-12-01), None
patent: WO 96/33719 (1996-10-01), None
patent: WO 01/70686 (2001-09-01), None
patent: WO 01/70745 (2001-09-01), None
Staub et al., New Paspalinine Derivatives with Antiinsectan Activity From the Sclerotia of Aspergillus Nomius, Tetrahedron Letters, vol. 34, No. 16, pp. 2569-2572, 1993.
Stephen R. Moore, et al., Invest. Ophthalmol. Vis. Sci., “Development and Aging of Cell topography in the Human Retinal Pigment Epithelium”, (1997), vol. 38, No. 10, pp. 2016-2026.
Robert A. Schumer, Arch. Opthalmol, “The Nerve of Glaucoma”, (1994), vol. 112, pp. 37-44.
Dandona, et al., Invest. Ophthalmol. Vis. Sci., “Selective Effects of Experimental Glaucoma on Axonal Transport by Retinal anglion Cells to the Dorsal Lateral Geniculate Nucleus”, (1991), vol. 32, No. 5, pp. 1593-1599.
Garcia Maria L.
Goetz Michael A.
Kaczorowski Gregory J.
McManus Owen B.
Monaghan Richard L.
Ayler Sylvia A.
Chung Susannah
Krovatin William
Merck & Co. , Inc.
Saeed Kamal A.
LandOfFree
Maxi-k channel blockers, methods of use and process for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Maxi-k channel blockers, methods of use and process for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Maxi-k channel blockers, methods of use and process for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3838485